TWI738648B - 含有ｉｌ－３１拮抗劑作為有效成分之異位性皮膚炎的預防用及／或治療用醫藥組合物 - Google Patents

含有ｉｌ－３１拮抗劑作為有效成分之異位性皮膚炎的預防用及／或治療用醫藥組合物 Download PDF

Info

Publication number
TWI738648B
TWI738648B TW105111451A TW105111451A TWI738648B TW I738648 B TWI738648 B TW I738648B TW 105111451 A TW105111451 A TW 105111451A TW 105111451 A TW105111451 A TW 105111451A TW I738648 B TWI738648 B TW I738648B
Authority
TW
Taiwan
Prior art keywords
weeks
administration
atopic dermatitis
antibody
group
Prior art date
Application number
TW105111451A
Other languages
English (en)
Chinese (zh)
Other versions
TW201642905A (zh
Inventor
金子晃久
岩柳有起
北村秀智
樋口義信
松下浩明
三原良介
山本裕美
齋藤智久
廣川恵子
Original Assignee
日商中外製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商中外製藥股份有限公司 filed Critical 日商中外製藥股份有限公司
Publication of TW201642905A publication Critical patent/TW201642905A/zh
Application granted granted Critical
Publication of TWI738648B publication Critical patent/TWI738648B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW105111451A 2015-04-14 2016-04-13 含有ｉｌ－３１拮抗劑作為有效成分之異位性皮膚炎的預防用及／或治療用醫藥組合物 TWI738648B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2015082699 2015-04-14
JP2015-082699 2015-04-14
JP2016041641 2016-03-04
JP2016-041641 2016-03-04

Publications (2)

Publication Number Publication Date
TW201642905A TW201642905A (zh) 2016-12-16
TWI738648B true TWI738648B (zh) 2021-09-11

Family

ID=57126544

Family Applications (4)

Application Number Title Priority Date Filing Date
TW113123713A TW202515609A (zh) 2015-04-14 2016-04-13 含有il-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物
TW112106953A TW202327654A (zh) 2015-04-14 2016-04-13 含有il-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物
TW105111451A TWI738648B (zh) 2015-04-14 2016-04-13 含有ｉｌ－３１拮抗劑作為有效成分之異位性皮膚炎的預防用及／或治療用醫藥組合物
TW110129891A TWI826814B (zh) 2015-04-14 2016-04-13 含有il-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
TW113123713A TW202515609A (zh) 2015-04-14 2016-04-13 含有il-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物
TW112106953A TW202327654A (zh) 2015-04-14 2016-04-13 含有il-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW110129891A TWI826814B (zh) 2015-04-14 2016-04-13 含有il-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物

Country Status (14)

Country Link
US (2) US10544227B2 (enExample)
EP (1) EP3284480B1 (enExample)
JP (6) JP6654967B2 (enExample)
KR (1) KR20170134748A (enExample)
CN (1) CN107614016B (enExample)
BR (1) BR112017022101A2 (enExample)
CA (1) CA2980992C (enExample)
MA (1) MA43918A (enExample)
MX (2) MX390570B (enExample)
NO (1) NO2025047I1 (enExample)
PT (1) PT3284480T (enExample)
RU (1) RU2749512C2 (enExample)
TW (4) TW202515609A (enExample)
WO (1) WO2016167263A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3284480T (lt) 2015-04-14 2025-08-11 Chugai Seiyaku Kabushiki Kaisha Farmacinė kompozicija, skirta atopinio dermatito profilaktikai ir (arba) gydymui, savo sudėtyje turinti il-31 antagonistą kaip veikliąją medžiagą
MX390570B (es) 2015-04-14 2025-03-20 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
WO2017126488A1 (ja) * 2016-01-18 2017-07-27 持田製薬株式会社 乾癬治療用組成物および治療方法
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
DK3749353T3 (da) * 2018-02-09 2025-09-01 Galderma Holding SA Nemolizumab til behandling af atopisk dermatitis med moderat til svær excoriation
PL3797752T3 (pl) 2018-05-21 2024-10-28 Chugai Seiyaku Kabushiki Kaisha Preparat liofilizowany szczelnie zamknięty w pojemniku szklanym
SG11202106478UA (en) * 2019-01-03 2021-07-29 Invetx Inc Compositions for increasing half-life of a therapeutic agent in canines and methods of use
EP4021499A4 (en) * 2019-08-29 2024-08-07 Elanco US Inc. ANTI-IL31 ANTIBODIES FOR VETERINARY USE
CN110563844A (zh) * 2019-09-04 2019-12-13 华中农业大学 一种抗犬白介素31受体的多克隆抗体及其应用
EP4062933A4 (en) 2019-11-20 2023-12-13 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
US20230047844A1 (en) * 2020-01-24 2023-02-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Compounds and methods for treating or reducing pruritus
JPWO2022113316A1 (enExample) * 2020-11-30 2022-06-02
TW202304510A (zh) * 2021-04-07 2023-02-01 瑞士商葛德瑪控股公司 結節性癢疹之治療
CN115181183B (zh) * 2022-06-23 2023-11-03 恺佧生物科技(上海)有限公司 一种il-31ra抗体以及其构建方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201028165A (en) * 2008-12-05 2010-08-01 Chugai Pharmaceutical Co Ltd Anti-NR10 antibody, and use thereof

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH575014A5 (enExample) 1973-05-25 1976-04-30 Alusuisse
JPS5328498Y2 (enExample) 1973-08-17 1978-07-18
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
BR9204244A (pt) 1992-10-26 1994-05-03 Cofap Ferro fundido cinzento
EP0671951A4 (en) 1992-12-01 1997-05-21 Protein Design Labs Inc HUMANIZED ANTIBODIES REACTING WITH L-SELECTIN.
FR2729855A1 (fr) 1995-01-26 1996-08-02 Oreal Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
CN1241944A (zh) 1996-12-05 2000-01-19 乔治敦大学 具有抗病毒活性的鼠尾草种类的提取物
JPH11101542A (ja) 1997-09-29 1999-04-13 Sanyo Electric Co Ltd 冷蔵庫
ATE314396T1 (de) 1998-04-30 2006-01-15 Tanox Inc G-csf-rezeptoragonist-antikörper und methode zu ihrer isolierung mittels durchmusterung
FR2780062B1 (fr) 1998-06-17 2000-07-28 Rhone Poulenc Rorer Sa Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
WO1999067290A1 (fr) 1998-06-24 1999-12-29 Chugai Research Institute For Molecular Medicine, Inc. Nouvelles proteines receptrices d'hemopoïetine
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
AU4952400A (en) 1999-06-02 2000-12-28 Chugai Research Institute For Molecular Medicine, Inc. Novel hemopoietin receptor protein nr10
EP1221482B1 (en) 1999-09-27 2005-12-28 Chugai Seiyaku Kabushiki Kaisha Hemopoietin receptor protein, nr12
CN1326880A (zh) 2000-06-06 2001-12-19 周伟中 双层站台火车站
ES2593002T3 (es) 2000-06-26 2016-12-05 Zymogenetics, Inc. Receptor ZCYTOR17 de citocina
US20030096339A1 (en) 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
WO2002077230A1 (fr) 2001-03-26 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Variants d'epissage nr10
JP4230776B2 (ja) 2001-04-05 2009-02-25 株式会社 免疫生物研究所 抗オステオポンチン抗体およびその用途
DK2230299T3 (da) 2002-01-18 2012-03-26 Zymogenetics Inc Hidtil ukendt cytokin ZCYTOR17-ligand
WO2004003140A2 (en) 2002-01-18 2004-01-08 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
ATE431406T1 (de) 2002-02-25 2009-05-15 Genentech Inc Neuer typ-1-cytokinrezeptor glm-r
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
ES2354419T3 (es) 2002-05-01 2011-03-14 Bayer Schering Pharma Aktiengesellschaft Nuevas proteínas de fusión de trombomodulina dirigidas hacia el factor tisular como agentes anticoagulantes.
TW200407335A (en) 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
KR100499989B1 (ko) 2002-12-27 2005-07-07 네오바이오다임 주식회사 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 면역크로마토그래피 스트립 및 이 스트립를 이용한 아사이알로 α1-산 당단백질 측정방법
US20040223970A1 (en) 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
EP1605974B1 (en) 2003-03-04 2014-11-12 Alexion Pharmaceuticals, Inc. Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
MXPA05010136A (es) 2003-03-24 2005-11-16 Zymogenetics Inc Anticuerpos anti-il-22ra, metodos y moleculas de enlace que se usan en la inflamacion.
WO2005079566A2 (en) 2004-02-12 2005-09-01 Lexicon Genetics Incorporated Gene disruptions, compositions and methods relating thereto
WO2006004663A2 (en) 2004-06-25 2006-01-12 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
KR100624013B1 (ko) 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
EP1671642A1 (en) 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
CN102977213B (zh) 2004-12-28 2017-05-24 依奈特制药公司 抗nkg2a 的单克隆抗体
WO2006081573A2 (en) 2005-01-28 2006-08-03 Zymogenetics, Inc. Homogeneous preparations of il-31
US20060188499A1 (en) 2005-02-14 2006-08-24 Leung Donald Y Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
JP2008530132A (ja) 2005-02-14 2008-08-07 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
MX2007013609A (es) * 2005-05-06 2008-01-24 Zymogenetics Inc Anticuerpos monoclonales de il-31 y meodos de uso.
MX2008008831A (es) 2006-01-10 2009-03-04 Zymogenetics Inc Metodos para tratar dolor e inflamacion en tejidos neuronales usando antagonistas il-31.
EP3101033B1 (en) 2006-01-12 2019-01-02 Alexion Pharmaceuticals, Inc. Antibodies to ox-2/cd200 and uses thereof
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
DK2047863T3 (da) 2006-06-08 2013-09-16 Chugai Pharmaceutical Co Ltd Middel til forebyggelse eller behandling af inflammatoriske sygdomme
ES2415655T3 (es) 2006-06-15 2013-07-26 The Board Of Trustees Of The University Of Arkansas Anticuerpos monoclonales que reconocen selectivamente Metanfetamina y compuestos similares a Metanfetamina
CA2660175C (en) 2006-09-01 2015-05-12 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
CN101600456A (zh) * 2006-12-11 2009-12-09 惠氏公司 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物
WO2008073463A2 (en) 2006-12-11 2008-06-19 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
DE602008004296D1 (de) 2007-02-14 2011-02-17 Vaccinex Inc Humanisierte anti-cd100-antikörper
AR065420A1 (es) 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
EP2138576A4 (en) 2007-03-16 2011-02-23 Kyowa Hakko Kirin Co Ltd ANTI-CLAUDIN-4 ANTIBODY
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
WO2009007272A1 (en) 2007-07-10 2009-01-15 F. Hoffmann-La Roche Ag Novel formulation
CA3139492C (en) 2007-09-26 2024-04-30 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
TWI578998B (zh) 2007-09-26 2017-04-21 中外製藥股份有限公司 抗ｉｌ－６受體的抗體
MY177564A (en) 2007-12-05 2020-09-20 Chugai Pharmaceutical Co Ltd Anti-nr10 antibody and use thereof
RU2541780C2 (ru) * 2007-12-05 2015-02-20 Чугаи Сейяку Кабусики Кайся Терапевтическое средство от зуда
ES2570853T3 (es) 2007-12-07 2016-05-20 Zymogenetics Inc Moléculas de anticuerpo humanizadas específicas para IL-31
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
EP3679942A1 (en) 2009-06-17 2020-07-15 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
JP6176849B2 (ja) 2011-07-19 2017-08-09 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
NZ731864A (en) 2012-09-07 2022-07-01 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
US9198898B2 (en) * 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
WO2014208645A1 (ja) * 2013-06-28 2014-12-31 中外製薬株式会社 そう痒を伴う疾患に罹患した患者のｉｌ－３１アンタゴニストによる治療に対する応答を予測する方法
MX390570B (es) * 2015-04-14 2025-03-20 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
GB201703063D0 (en) 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
WO2018156367A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
CN118697867A (zh) 2017-04-11 2024-09-27 基尼克萨制药有限公司 稳定的抗osmr抗体制剂
PL3797752T3 (pl) 2018-05-21 2024-10-28 Chugai Seiyaku Kabushiki Kaisha Preparat liofilizowany szczelnie zamknięty w pojemniku szklanym
EP4062933A4 (en) 2019-11-20 2023-12-13 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
MX2023002482A (es) 2020-09-01 2023-03-08 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201028165A (en) * 2008-12-05 2010-08-01 Chugai Pharmaceutical Co Ltd Anti-NR10 antibody, and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
根本治等: 健康成人男性及びアトピー性皮膚炎患者を対象としたIL31 受容体抗体 の第I 相試験.日本皮膚科学会雑誌,124 巻 (2014) 4 号,p779〔P7-5〕. *
根本治等: 健康成人男性及びアトピー性皮膚炎患者を対象としたIL31 受容体抗体CIM331 の第I 相試験.日本皮膚科学会雑誌,124 巻 (2014) 4 号,p779〔P7-5〕.

Also Published As

Publication number Publication date
RU2017138551A (ru) 2019-05-14
EP3284480A1 (en) 2018-02-21
US20200102396A1 (en) 2020-04-02
CA2980992C (en) 2024-01-23
MA43918A (fr) 2018-12-05
NO2025047I1 (no) 2025-10-23
PT3284480T (pt) 2025-07-29
CA2980992A1 (en) 2016-10-20
US11773173B2 (en) 2023-10-03
TW201642905A (zh) 2016-12-16
US20180079817A1 (en) 2018-03-22
RU2749512C2 (ru) 2021-06-11
WO2016167263A1 (ja) 2016-10-20
JP2017160178A (ja) 2017-09-14
JP6887212B2 (ja) 2021-06-16
CN107614016B (zh) 2022-06-17
US10544227B2 (en) 2020-01-28
MX2021013139A (es) 2021-11-25
JP2025122131A (ja) 2025-08-20
JP2021105051A (ja) 2021-07-26
JP2021193124A (ja) 2021-12-23
EP3284480B1 (en) 2025-07-02
JP2023134842A (ja) 2023-09-27
TW202327654A (zh) 2023-07-16
TWI826814B (zh) 2023-12-21
EP3284480A4 (en) 2018-12-05
RU2017138551A3 (enExample) 2019-09-30
BR112017022101A2 (pt) 2018-07-31
TW202146048A (zh) 2021-12-16
JP6654967B2 (ja) 2020-02-26
MX2017013141A (es) 2018-02-21
TW202515609A (zh) 2025-04-16
CN107614016A (zh) 2018-01-19
MX390570B (es) 2025-03-20
KR20170134748A (ko) 2017-12-06
JP2020075937A (ja) 2020-05-21

Similar Documents

Publication Publication Date Title
TWI738648B (zh) 含有ｉｌ－３１拮抗劑作為有效成分之異位性皮膚炎的預防用及／或治療用醫藥組合物
KR102800698B1 (ko) Il-31 안타고니스트를 유효 성분으로서 함유하는, 투석 소양증의 예방용 및/또는 치료용 의약 조성물
AU2022201346B2 (en) Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing IL-31 antagonist as active ingredient
JP2023182632A (ja) 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ
TWI871349B (zh) 含有il-31拮抗劑作為有效成分之透析搔癢症的預防用及/或治療用醫藥組合物
RU2806304C1 (ru) Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента
HK40078297A (en) Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
HK40084397A (en) Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient
HK1246643A1 (en) Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
HK1246643B (en) Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient